Driving Smarter Market Access in a Complex Healthcare World

The Center of Excellence (COE) for Market Access, Pricing, and HEOR empowers clients with the intelligence, strategies, and solutions needed to succeed in rapidly evolving healthcare landscapes. Through thought leadership and global collaboration, we transform insights into action.

Our Mission

At the heart of our work is a simple mission: to drive exceptional market access outcomes. We do this by combining real stakeholder perspectives with practical solutions, giving our clients clarity and confidence as they navigate shifting healthcare systems worldwide.

Leadership team

Our team brings together expertise in market access, evidence generation, and pricing strategy.

  • Andrea L. Monteiro, PhD leads the COE.

  • Susanne Michel focuses on HTA and evidence.

  • Michael Epstein drives commercial and pricing strategy.

  • Oliver Yao specializes in global market access.

Together, they connect clients with decision-makers and deliver solutions that are as strategic as they are actionable.

How we work

The COE thrives on collaboration. We track policy reforms, HTA developments, and reimbursement changes across Europe, the US, LATAM, APAC, and Canada. By engaging directly with payers and HTA experts, we generate real-time intelligence and translate it into strategies that support better access for innovative therapies.

Our output is diverse and continuous: white papers that shape the conversation, webinars that bring experts together, policy briefs that clarify complex issues, and roundtables that enable frank dialogue between stakeholders.

Research Priorities 2025-2026

In the coming year, our work will concentrate on challenges that matter most to healthcare innovators and decision-makers. We are developing country-specific market access roadmaps, exploring new ways to demonstrate value for rare diseases, and assessing how policies like the Inflation Reduction Act will affect pricing and contracting. We are also working on sustainable access models, EU HTA implementation, and affordability solutions for high-cost therapies.

Fill in the form to register and be the first to know when the next piece of thought leadership is live!

Content calendar August - October 2025

August
  • Value CMS Cell & Gene Therapy Access Model
  • HTA & JCA Requirements for Rare Diseases
  • China’s Paradigm Shift: How Eastern Innovation could Reshape Access
  • AI in Market Access: What It Can and Cannot Do
  • Value of 2nd-to-Market Gene Therapies
September
  • Global Launch Sequencing Strategies
  • Impact of the Inflation Reduction Act on US Pricing & Access
  • Country-Level Access Roadmaps
October
  • Recognised RWE Data Sources for HTAs
  • Sustainable access solutions ahead of formal reimbursement
  • Pricing of early access programs